Browsing by Author "Onal, C."

Now showing 1 - 5 of 5

Concurrent cisplatin and radiotherapy versus cetuximab and radiotherapy, an unsolved problem
(OXFORD UNIV PRESS, 2018-01-01) Guler, O. C.; Onal, C.; Ozyar, E.
National, Observational, Multicentric Study in Stage III Non-Small Cell Lung Cancer Patients in Turkey: Stone Trial
(2019-01-01) Onal, C.; Demiral, A.; Atalar, B.; Yalman, D.; Gul, S.; Hurmuz, P.; Erpolat, P.; Akyurek, S.; Berber, T.; Guler, O.; Umay, C.; Sert, F.; Dagoglu, N.; Yaprak, G.; Karahacioglu, E.; Birgi, S. Duru; Saglam, E. Kaytan
Outcome and prognosticators in adult patients with medulloblastoma: a Rare Cancer Network study
(ELSEVIER IRELAND LTD, 2016-01-01) Atalar, B.; Ozsahin, M.; Call, J.; Napieralska, A.; Kamer, S.; Salvador, V.; Erpolat, P.; Negretti, L.; Ramstad, Y. L.; Onal, C.; Akyurek, S.; Ugurluer, G.; Baumert, B.; Servagi-Vernat, S.; Miller, R. C.; Ozyar, E.; Sio, T.
The effect of TAB duration and pelvic RT in prostate cancers with gleason score 8-10: TROG study
(ELSEVIER IRELAND LTD, 2017-01-01) Ozyigit, G.; Onal, C.; Igdem, S.; Alicikus, Z. Arican; Iribas, A.; Akin, M.; Yalman, D.; Cetin, I.; Aksu, M. G.; Atalar, B.; Dincbas, F.; Aydin, B.; Sert, F.; Yildirim, C.; Gorken, I. B.; Agaoglu, F. Y.; Korcum, A. F.; Ozkok, S.; Darendeliler, E.; Akyol, F.
Treatment results and prognostic factors in primary thyroid lymphoma patients: a Rare Cancer Network study
(OXFORD UNIV PRESS, 2011-01-01) Onal, C.; Li, Y. X.; Miller, R. C.; Poortmans, P.; Constantinou, N.; Weber, D. C.; Atasoy, B. M.; Igdem, S.; Ozsahin, M.; Ozyar, E.
Background: This study analyzed prognostic factors and treatment outcomes of primary thyroid lymphoma. Patients and Methods: Data were retrospectively collected for 87 patients (53 stage I and 34 stage II) with median age 65 years. Fifty-two patients were treated with single modality (31 with chemotherapy alone and 21 with radiotherapy alone) and 35 with combined modality treatment. Median follow-up was 51 months. Results: Sixty patients had aggressive lymphoma and 27 had indolent lymphoma. The 5- and 10-year overall survival (OS) rates were 74\% and 71\%, respectively, and the disease-free survival (DFS) rates were 68\% and 64\%. Univariate analysis revealed that age, tumor size, stage, lymph node involvement, B symptoms, and treatment modality were prognostic factors for OS, DFS, and local control (LC). Patients with thyroiditis had significantly better LC rates. In multivariate analysis, OS was influenced by age, B symptoms, lymph node involvement, and tumor size, whereas DFS and LC were influenced by B symptoms and tumor size. Compared with single modality treatment, patients treated with combined modality had better 5-year OS, DFS, and LC. Conclusions: Combined modality leads to an excellent prognosis for patients with aggressive lymphoma but does not improve OS and LC in patients with indolent lymphoma.